Top

Supportive Care in Cancer

Published in:

Open Access 01-02-2017 | Letter to the editor

Response to letter to the Editors—Safety of long-term denosumab therapy

Authors: Alison T. Stopeck, Douglas J. Warner

Published in: Supportive Care in Cancer | Issue 2/2017

Excerpt

Dear Editors, …

Fusco V, Bedogni A, Addeo A, Campisi G (2016) Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study? Support Care Cancer

Boissieu P, Trenque T (2016) Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab. Support Care Cancer

Stopeck A, Fizazi K, Body J, Brown J, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24(1):447–455CrossRefPubMedPubMedCentral

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, Boer R, Lichinitser M, Fujiwara Y, Yardley D, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double blind study. J Clin Onc 28(35):5132–5139CrossRef

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822CrossRefPubMedPubMedCentral

XGEVA® (denosumab) US Package Insert (2014) Amgen Inc

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRefPubMed

Title: Response to letter to the Editors—Safety of long-term denosumab therapy
Authors: Alison T. Stopeck
Douglas J. Warner
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3492-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

The role of palliative care in the last month of life in elderly cancer patients

Palliative care consultation team on acute wards—an intervention study with pre-post comparisons

Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials

Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity

Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications

Axillary web syndrome is not a risk factor for lymphoedema after 10 years of follow-up

Keynote webinar | Spotlight on antibody–drug conjugates in cancer